Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,904 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT05739331Recruiting
AI-assisted breathing test to check swollen chest lymph nodes
This trial uses an AI-supported breathing procedure to help doctors examine enlarged lymph nodes in the chest when the cause is still unknown. It may help improve how accurately and efficiently doctors assess these lymph nodes so you can get answers sooner.
LevangerAges 18 years+ - NCT05748093RecruitingPhase 4
Boost osimertinib levels using cobicistat to improve value
This study tests whether adding cobicistat can increase and stabilize the effect level of osimertinib while keeping treatment cost-effective. You would take osimertinib 80 mg daily, with blood tests to see how your body processes the drug.
Maastricht, LimburgAges 18 years+ - NCT05751798RecruitingPhase 1/Phase 2
Test drug OSE-279 for advanced lung cancer that has no key mutations
This Phase 1/2 study tests how well and how safely OSE-279 works in people with advanced non-small cell lung cancer (NSCLC) who cannot be cured with surgery or radiation. It also looks at the right dose and how it may help, especially if the tumor has high PD-L1.
AnderlechtAges 18 years+ - NCT05754203Recruiting
Radiation plus immunotherapy for advanced lung cancer
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05777278RecruitingPhase 1/Phase 2
Savolitinib plus docetaxel for advanced lung cancer with high MET
This trial studies savolitinib (an oral MET-targeted medicine) combined with docetaxel (an IV chemotherapy) in people with advanced non-small cell lung cancer (NSCLC) whose tumor has high MET activity. It’s designed to see if this combination can shrink tumors or control the cancer after the first standard treatment.
Guangzhou, GuangdongAges 18 years+ - NCT05800340RecruitingPhase 2
Immunotherapy before surgery for certain rare lung cancer mutations
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
Guanzhou, GuangdongAges 18 years+ - NCT05893888RecruitingPhase 2/Phase 3
Testing three investigational drugs for mouth and lung cancers
This trial tests whether PRV111, PRV211, and PRV131 are safe and work better than expected for certain mouth (lip/oral cavity) cancers and lung cancers. It may help by trying a new approach given directly to the tumor and then monitoring how well it shrinks and how safe it is.
Duarte, CaliforniaAges 18–100 - NCT06068049Recruiting
Study of osimertinib in patients with EGFR-mutated lung cancer in Spain
This study is looking back at how people with EGFR-mutated non-small cell lung cancer who have taken osimertinib (Tagrisso) actually did in everyday medical care in Spain. It includes patients who took osimertinib in several different treatment scenarios.
A CoruñaAges 18 years+ - NCT06080776RecruitingPhase 3
SH-1028 vs placebo for early-stage EGFR-mutated lung cancer
This trial tests a pill called SH-1028 (an EGFR-targeted drug) versus a placebo to see if it helps prevent lung cancer from coming back after surgery in people with EGFR-mutated NSCLC. You may be eligible if you had complete removal of stage II-IIIB NSCLC and your tumor has a specific EGFR mutation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06084806RecruitingPhase 2
Testing reliability of a new PET scan for NSCLC on immunotherapy
This study tests a new PET imaging agent to see how consistently it shows immune activity in the body. It is for people with advanced non-small cell lung cancer who are about to start immunotherapy.
Iowa City, IowaAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT06111807Recruiting
Validating blood tests for stage III lung cancer
This trial is testing whether new blood tests can reliably detect and monitor stage III non-small cell lung cancer (NSCLC). It hopes to improve how doctors track your cancer and decide on treatment.
Nice, NiceAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06141070RecruitingPhase 3
Adding high-dose radiation to standard treatment for advanced lung cancer
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
GothenburgAges 18 years+ - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06195189RecruitingPhase 1/Phase 2
Sunvozertinib Plus Chemo for EGFR Lung Cancer After TKI Failure
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
Chengdu, SichuanAges 18–80 - NCT06195527Recruiting
Pembrolizumab blood level monitoring for NSCLC
This study checks how well pembrolizumab (Keytruda) works in people with non-small cell lung cancer (NSCLC) by measuring the drug levels in your blood. It aims to see if adjusting the dose based on these levels improves treatment and reduces side effects.
AngersAges 18 years+ - NCT06221800Recruiting
Gut bacteria and lung cancer treatment side effects study
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
Orange, CaliforniaAges 18 years+ - NCT06223711RecruitingPhase 2
Durvalumab with radiation therapy for limited-spread small cell lung cancer
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
Augsburg, BavariaAges 18 years+ - NCT06228482RecruitingPhase 1
Targeted radioactive therapy for advanced lung cancer
This trial tests a new targeted radioactive drug that seeks out a specific marker on lung cancer cells. It first uses a low-dose imaging scan to see if the cancer cells have this marker, then gives a higher-dose treatment to destroy those cells.
Sacramento, CaliforniaAges 18 years+ - NCT06232265Recruiting
Predicting Immunotherapy Success in Lung Cancer
This study looks at how well a test called LIRAscore can predict whether immunotherapy will work for people with advanced non-small cell lung cancer. You will receive standard immunotherapy (with or without chemotherapy), and researchers will check your tumor samples for certain markers.
Guangzhou, GuangdongAges Any age - NCT06258642Recruiting
Irinotecan liposome plus anlotinib for SCLC after first chemo
This trial tests a combination of two drugs—irinotecan liposome (a chemotherapy) and anlotinib (a targeted therapy)—as a second treatment for small cell lung cancer that returned quickly after initial chemo. The goal is to see if this combo can work better than standard options.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,904 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.